Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
Pilot Studies Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Fitzpatrick Skin Type I - IIII * Self-identified rosacea or no history of flushing/blushing for controls * Able to provide medical history and list of medications -- control subjects will not be allowed to take medications that are known to be photosensitizers. Exclusion Criteria: * Using imipramine, amitriptyline or any other tricyclic antidepressant (oral or topical) * Using topical anti-inflammatory (within 1 week) or systemic agents (e.g. prednisone) * Large tattoos in the designated testing areas * Tanning bed use within last 3 months * Photodynamic Therapy or UCB treatments in past 3 months * Female Subjects: pregnant or nursing
About the study
Rosacea is a common skin condition associated with easy blushing and red face; many patients with rosacea react to sunlight with increased redness. The purpose of this study is to determine if the use of a topical medication will help reduce sunlight induced redness and irritation in patients with rosacea.
What is being tested
- Imipramine (drug)
- Amitriptyline (drug)
- Vehicle (drug)
Sponsor: Wright State University · Participants: 48 · Started: Feb 27, 2024
Contact the study team
- Manager Clinical Research Operations · Phone: (937)-245-7500
Official record on ClinicalTrials.gov — NCT06312813
Locations in the U.S.
| Ohio | Wright State Physicians, Fairborn |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.